ACE2_MOUSE Ace2 ELISA tesk kit
- Known as:
- ACE2_MOUSE Ace2 Enzyme-linked immunosorbent assay test tesk reagent
- Catalog number:
- gen17517
- Product Quantity:
- 1
- Category:
- Peptides
- Supplier:
- Other suppliers
- Gene target:
- ACE2_MOUSE Ace2 ELISA tesk kit
Related genes to: ACE2_MOUSE Ace2 ELISA tesk kit
- Gene:
- ACE2 NIH gene
- Name:
- angiotensin I converting enzyme 2
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- Xp22.2
- Locus Type:
- gene with protein product
- Date approved:
- 2000-09-25
- Date modifiied:
- 2016-10-05
Related products to: ACE2_MOUSE Ace2 ELISA tesk kit
Related articles to: ACE2_MOUSE Ace2 ELISA tesk kit
- The antibodies (including 7C4, 8D1) are neutralizing antibodies specifically targeting the protein RBD, a key core of the combination with angiotensin-converting enzyme 2 (ACE2). In order to measure HuB01 in fermentation products accurately, a bioanalytical method was needed, which should have high selectivity and be free from interference by 501Y.V2. - Source: PubMed
Publication date: 2026/06/12
Liu YuyingZhang YaoLi LingChen DanYang ZengminLiu YunYu XinyuLiu YongjiangZhang Haijiang - A performance evaluation of a quantitative research use only (RUO) immunological assay utilizing the Meso Scale Discovery (MSD) platform for assessing IgM, IgA, and IgG binding and SARS-CoV-2 pseudo-neutralization was performed. Comparative analyses of antibody quantification of IgA, IgG, and IgM isotypes against SARS-CoV-2 nucleocapsid, spike, Receptor Binding Domain (RBD) and N-Terminal Domain (NTD) antigens were performed using MSD multi-spot electro-chemiluminescent V-PLEX COVID-19 test kits, and two well characterized serological panels. Cross reactivity was assessed against COVID-19 negative/Influenza samples. Precision was assessed by comparing variation between duplicate values within run; accuracy was assessed by comparing values obtained across runs against expected values. The MSD IgG, IgA, and IgM binding, and ACE2 inhibitory antibody assays demonstrated acceptable precision and accuracy within the expected 20%/30% variability, respectively per manufacturer's protocol; no cross reactivity with influenza samples was observed. Different MSD plate configurations, multiple (two) MSD analysis instruments, and multiple operators did not impact antibody quantification; thus, confirming the robustness of both assays. Comparative analysis between MSD and commercial Euroimmun, Siemens ADVIA, and Beckman Coulter DXLTM ACCESS assays demonstrated better performance overall for the MSD assay. IMPORTANCE: This work describes and validates the MSD platform, as a highly flexible, customizable, operator independent, and reliable platform for antibody assessment of COVID-19 response which is highly adaptable to immune assessment of emerging or re-emerging pathogens. - Source: PubMed
Publication date: 2026/06/12
Cincotta Camila MacedoColeman DantePadilla StevenEnoch JenniferNaouar Ines Lakhal-Bell MatthewOuellette JasonMansouri SheidaM'hamdi OussamaDarden JaniceMalia JenniferPeel Sheila APeachman Kristina K - This narrative review examines acute and chronic kidney injury following COVID-19 infection and vaccination, discussing the mechanism of SARS-CoV-2 entry into host cells through the ACE2 receptor - highly expressed in renal tissues - facilitating the viral invasion. Viral RNA has been detected in the urine of patients infected with SARS-CoV-2, suggesting direct renal involvement. The incidence of acute kidney injuriy (AKI) among hospitalized COVID-19 patients was particularly higher in the early stages of the pandemic and largely varied by 29%-46%, depending on population studied and COVID-19 wave. Pathological findings include acute tubular injury (ATI), collapsing glomerulopathy, and focal segmental glomerulosclerosis. Major risk factors for AKI comprise older age, male sex, diabetes, hypertension, cardiovascular disease, and preexisting Chronic Kidney Disease (CKD). AKI significantly increases mortality of COVID-19 patients, particularly in advanced stages of renal failure. CKD is also associated with severe COVID-19 outcomes, including increased hospitalization, intensive care admission, and mortality. Patients with CKD show a dose-dependent relationship between disease stage and adverse patient outcomes. This review further addresses renal complications following COVID-19 vaccination, which, although rare, encompass various immune-mediated glomerular diseases. Minimal Change Disease (MCD) is most frequently reported after COVID-19 vaccination, followed by IgA nephropathy, membranous nephropathy, anti-glomerular basement membrane (anti-GBM) nephritis, and ANCA-associated vasculitis. These conditions commonly present with hematuria, proteinuria, or nephrotic syndrome, and many respond to corticosteroid or immunosuppressive therapy. Other less frequent renal complications include thrombotic microangiopathy, acute tubulointerstitial nephritis, and IgG4-related nephritis. In conclusion, both COVID-19 infection and vaccination can be associated with a spectrum of renal manifestations ranging from AKI to CKD and immune-mediated glomerulopathies. Awareness, early detection, and multidisciplinary management are essential to reduce renal morbidity and improve patient outcomes. - Source: PubMed
Publication date: 2026/06/11
Saadat Seyed HassanJavanbakht MohammadAmini HosseinRouhollahei MahboubehCegolon LucaEinollahi Behzad - The purpose of this article is to investigate the expression of neuropeptide family members and their correlation with inflammatory indicators in the peripheral blood of children infected with COVID-19. - Source: PubMed
Publication date: 2026/06/09
Li Hong WeiWu Shang ZhiTang Si XiangZhao LiLu Cheng YuLeung Alexander K CHon Kam LunChen De Hui - Severe hyperglycemia during acute COVID-19 infection is an uncommon but clinically significant presentation. Here, we present an unusual case of an 82-year-old COVID-19-positive man who presented with severe hyperglycemia following several days of COVID-19 symptoms, with an admission HbA1c of 14.7%. He received standard treatment for a working diagnosis of diabetic ketoacidosis (DKA), improved clinically, and was discharged after five days, but continued to require exogenous insulin to maintain appropriate fasting and postprandial blood glucose levels. This case represents possible COVID-19-associated metabolic decompensation in previously unrecognized type 2 diabetes. It highlights the importance of monitoring patients with COVID-19 for severe hyperglycemia and metabolic decompensation, particularly in elderly individuals, those with metabolic risk factors, or those with severe clinical presentations. - Source: PubMed
Publication date: 2026/05/11
Bullough CooperMatherne LeslieRhinehardt Jared